128 Million Americans Can't See Up Close. Your Best Techs Are Among Them

One hundred twenty eight million. That is how many Americans over 40 have presbyopia, the gradual loss of near vision that turns precision work into guesswork. The machinist reading a micrometer. The quality inspector checking a weld. The maintenance tech wiring a panel. Every one of them squinting a little harder each year. And now a UK drug filing just put a clock on whether that problem has a pharmaceutical fix headed for American shop floors.

The Signal

Tenpoint Therapeutics submitted a Marketing Authorization Application to the UK's Medicines and Healthcare Products Regulatory Agency for a presbyopia treatment targeting blurry closeup vision in adults. This is not a pair of reading glasses. It is a pharmaceutical intervention designed to restore functional near vision. The UK filing matters for American operators because ophthalmic products that clear MHRA review typically reach the FDA pipeline within 12 to 24 months. That puts a potential US market entry somewhere around 2027 or 2028.

If you run a plant, a distribution center, or a field services operation, this is not a pharma story. It is a workforce planning signal. The skilled labor crisis in manufacturing and energy is not theoretical. According to Federal Reserve data, the Industrial Production Index sat at 98.64 in May 2026, up only 1.8 percent from 96.93 in June 2024. That flat trajectory tells you something important. Output is not growing because capacity is not growing. And capacity is not growing because experienced operators are leaving faster than new ones arrive. Anything that keeps a 58 year old CNC programmer or a 62 year old instrument tech on the floor for two or three more years is not a nice to have. It is a strategic asset.

That flat production line is the backdrop for every workforce decision you make in the next 24 months. Output is barely moving. You cannot afford to lose the people holding it together.

Workforce Retention Gets a New Variable

The median age of a skilled machinist in the United States is north of 50. Electricians, pipefitters, and quality inspectors skew similarly. These are the people who carry institutional knowledge that no onboarding program can replicate. When a 60 year old instrument tech retires because he cannot read gauges without pulling out magnifiers, you do not just lose a headcount. You lose 30 years of tribal knowledge about why that particular heat exchanger trips every March.

Presbyopia accelerates the exit timeline. It is not the sole reason experienced operators retire, but it is a contributing factor that compounds alongside joint pain, fatigue, and general wear. Remove that variable and you potentially extend tenure by two to three years per affected worker.

Audit your workforce demographics now. Identify every operator over 50 in a role that requires consistent near vision. Machining, inspection, calibration, electrical termination, instrument reading. Count them. Model what happens if 20 percent of them delay retirement by 30 months. Then model what happens if they do not. The gap between those two scenarios is your exposure. Federal Reserve production data shows output crawling at barely 1.8 percent growth over two years. You are not in a position to absorb experience drain. If a pharmaceutical option reaches the US market, employers who have already mapped their exposure will move first on coverage decisions. Everyone else will be reacting.

Benefits Strategy Needs a Pharmaceutical Lane

Most industrial employers offer vision benefits that cover glasses, contacts, and annual exams. That framework was built for a world where corrective lenses were the only option. A presbyopia drug changes the calculus. The question for CFOs and HR leaders is whether vision benefit plans should expand to include pharmaceutical treatments that keep skilled workers operational.

This is not about generosity. It is about math. Replacing a senior maintenance technician costs between 100 and 150 percent of annual salary when you factor recruiting, onboarding, lost productivity during ramp up, and the mistakes a green replacement will make. If a pharmaceutical treatment costs a few hundred dollars per year and delays that replacement cycle by 24 to 36 months, the return is obvious.

Pull your benefits data. Look at vision claims for workers over 50 in critical roles. Talk to your benefits broker about pharmaceutical coverage carveouts for ophthalmic treatments. You do not need to wait for FDA approval to start the conversation. The UK filing is your signal to get the infrastructure ready. When the FDA pathway clears, you want to be in a position to offer coverage in the next open enrollment cycle, not two years after approval while your competitors already have it in place.

Safety and Compliance Exposure You Are Not Measuring

Here is the part nobody talks about openly. Near vision degradation is a safety risk. An electrician who misreads wire markings. A quality inspector who misses a hairline crack. A forklift operator who cannot read a load chart clearly. These are not hypothetical scenarios. They happen every day in facilities across the country. Most safety programs do not specifically screen for presbyopia progression. They check for distance vision. They check for color blindness. But the gradual loss of near focus that comes with age slides under the radar until an incident forces the conversation.

Add near vision acuity testing to your annual safety screening protocol. Not as a gatekeeping measure that pushes experienced workers out, but as a diagnostic tool that identifies who needs intervention. If pharmaceutical options become available, you want the baseline data to act on them. The Industrial Production Index hovering around 98 with minimal growth means every lost time incident and every quality escape hits your margins harder. You are running lean. Your experienced operators are the margin of safety between controlled production and chaos. Anything that keeps their eyes sharp is a safety investment, not a healthcare expense.

Succession Planning Cuts Both Ways

There is a less obvious implication here that deserves attention. If presbyopia treatments extend the working tenure of experienced operators by two to three years, that changes your succession math. On the upside, you get more runway to develop younger replacements. More time for knowledge transfer. More overlap between the outgoing expert and the incoming apprentice. On the downside, you may create a logjam. Younger workers waiting for advancement opportunities that do not open up. Wage compression as senior operators stay longer and newer hires stall at lower pay grades. Frustration that drives your next generation of talent to competitors who offer faster progression.

Assume a scenario where your over 55 workforce stays 30 months longer than current actuarial models predict. Map what that does to your promotion pipeline, your wage structure, and your training investment. Then build the alternative scenario where they leave on the current timeline. Your capital allocation between recruiting, training, and retention shifts dramatically between those two futures. The operators who plan for both will outperform those who get surprised by either outcome. This is not a 2030 problem. If the UK approval moves on schedule and the FDA follows within 18 to 24 months, you are looking at 2028. Your next strategic plan should have a line item for it.

The Forward View

A drug filing in London is not normally something that lands on an industrial operator's radar. But the workforce crisis in manufacturing, energy, and distribution has made strange bedfellows of pharma pipelines and production schedules. The question is not whether aging vision affects your operation. It does. The question is whether you are treating it as an inevitability or as a variable you can actually influence. The companies that start modeling now will not just retain talent longer. They will redefine what retirement ready means for an entire generation of skilled workers who still have years of value to deliver.

This article is part of the Industry Intelligence series on NeuralPress. New analysis published daily.